$CALC News

CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program

CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety Data

FDA Raises No Concerns Over Auxora Safety Data, CalciMedica Advances Trial

CalciMedica Announces Private Placement Worth Up To ~$49M In Gross Proceeds

CalciMedica Receives No FDA Comments On The Submission Packet For Its Phase 2 KOURAGE Trial, Meaning The Company May Continue To Dose Patients With Auxora

CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates

CalciMedica Q1 EPS $0.30 Beats $(0.28) Estimate

Oppenheimer Maintains Outperform on CalciMedica, Lowers Price Target to $10

CalciMedica shares are trading higher. The company reported Q4 financial results.

CalciMedica shares are trading higher. The company reported Q4 financial results.

CalciMedica Reports 2025 Financial Results and Provides Clinical Updates

CalciMedica Q4 EPS $(0.69) Misses $(0.42) Estimate

CalciMedica FY EPS $(1.97) Misses $(1.62) Estimate, Cash Balance Of $13M Provides Cash runway Into Q4 2026

How Is The Market Feeling About CalciMedica Inc?

CalciMedica shares are trading lower after HC Wainwright & Co. downgraded the stock from Buy to Neutral rating.

CalciMedica’s stock drops 75% on acute kidney injury trial termination

HC Wainwright & Co. Downgrades CalciMedica to Neutral

CalciMedica shares are trading lower after the company announced the discontinuation of its Phase 2 KOURAGE clinical trial evaluating Auxora in patients with Stage 2 or Stage 3 acute kidney injury with associated acute hypoxemic respiratory failure.

CalciMedica Pauses Kidney Study, Eyes New Trial In Pancreatitis

CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation